Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707745 | 0.98 | HDAC3 (0.38) | HDAC1HDAC3PARP14NAMPT | |
| SCHEMBL6711734 | 0.95 | PARP14 (0.37) | HDAC1HDAC3PARP14MMP2MMP9 | |
| SCHEMBL6707672 | 0.92 | RAB9A (0.40) | HDAC1HDAC3NPC1 | |
| SCHEMBL6709207 | 0.91 | PARP14 (0.43) | HDAC1HDAC3PARP14 | |
| SCHEMBL6711656 | 0.90 | GSK3B (0.42) | HDAC1HDAC3PARP14 | |
| SCHEMBL6710292 | 0.90 | GSK3B (0.40) | HDAC1HDAC3NPC1 | |
| SCHEMBL6713665 | 0.90 | HDAC3 (0.41) | HDAC1HDAC3NPC1 | |
| SCHEMBL6713357 | 0.90 | HDAC3 (0.41) | HDAC1HDAC3NPC1 | |
| SCHEMBL6710011 | 0.89 | NPC1 (0.45) | HDAC1HDAC3MMP2MMP13MMP9 | |
| SCHEMBL6710296 | 0.89 | ADORA3 (0.41) | HDAC1HDAC3MMP2MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HDAC1 1910/4885HDAC3 2281/4885PARP14 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.